Telix Pharmaceuticals (ASX:TLX) Accumulated other comprehensive income (loss) : A$184.4 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Telix Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Telix Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2024 was A$184.4 Mil.

Telix Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2023 (A$-33.7 Mil) to Jun. 2024 (A$50.1 Mil) and increased from Jun. 2024 (A$50.1 Mil) to Dec. 2024 (A$184.4 Mil).

Telix Pharmaceuticals's annual Accumulated other comprehensive income (loss) declined from Dec. 2022 (A$-18.2 Mil) to Dec. 2023 (A$-33.7 Mil) but then increased from Dec. 2023 (A$-33.7 Mil) to Dec. 2024 (A$184.4 Mil).

Telix Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Telix Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

4.92

4.79

-18.15

-33.69

184.40

Telix Pharmaceuticals Semi-Annual Data
	Sep00	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial												-18.15	-30.62	-33.69	50.07	184.40

Telix Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Telix Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (ASX:TLX) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA T3X:Germany

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.